By Clinical Research News Staff

October 8, 2026 | Brain organoids, three-dimensional tissues grown from stem cells, are edging closer to the clinic, with researchers envisioning a future in which a patient's response to a drug can be tested in a lab dish before they ever enroll in a study.

Paola Arlotta, Ph.D., a professor of stem cell and regenerative biology at Harvard University, says advances in organoid technology and artificial intelligence are converging to speed up and derisk drug development. Her team recently kept human brain organoids alive for a record six years, allowing them to study late developmental stages and postnatal maturation. The work, published in Nature, found that the organoids matured on a human timeline, with gene expression, DNA methylation patterns, synapses and electrical activity changing in ways that paralleled real brain development.

The clinical implications center on diseases that animal models have failed to capture. Arlotta points to autism, for which she notes there is no drug targeting core symptoms. Genetic studies have linked many variants to the condition, but they are often too complex to engineer in animals, and by the time a child sees a doctor, the brain has already developed. Instead, scientists can reprogram a patient’s blood cells into stem cells, then grow an organoid to watch early brain development unfold and test how that patient-specific replica responds to perturbations.

Arlotta says organoids may also reveal disease “fingerprints,” such as distinctive gene expression profiles or electrical properties that differ from organoids made from unaffected individuals. Those patterns could serve as the start and end points of a therapeutic search, with candidate drugs tested for their ability to shift a disease fingerprint toward the control pattern. The same approach could apply to neurodegenerative, psychiatric, and mood disorders.

A particular focus is predicting who will respond to treatment. Drugs that work in nervous system trials often fail to help everyone, and Arlotta notes that without a long, expensive trial, there is no way to predict who will benefit. She points to “chimeroids,” organoids that contain cells from many people, developed in her lab in 2024, as one route to answering that question. She also envisions using organoids from enrolled participants to estimate the probability that an individual will respond to a new intervention and feeding organoid data into AI models to create “virtual cells” that predict responses to genetic and drug interventions.

Longer term, Arlotta imagines “biological avatars” across multiple tissues that could forecast how the whole body will respond to a therapy before clinical trials begin.

Read Deborah Borfitz’s full story at Bio-IT World.